S2-E34 – #ILC2021 Day Three – Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon

Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021.

Most of the presentations the panel covered focused on medications, the core ideas and discussions spoke to changes in thinking. One theme that ran through the discussion was about multi-disciplinary care…and not only because Fatty Liver Endocrinologist Ken Cusi was on the panel. Another was to think about drugs for NASH holistically. In all, this podcast takes the broad view and the long view on treating Fatty Liver diseases, and should provoke new thoughts and ideas in you the listener.

TOPICS: Akero Therapeutics, cirrhosis, COVID-19, Diabetes, Fatty Liver, FibroScan, Fibrosis Level 3, Fibrosis Level 4, inventiva, lanifibranor, NAFLD, NASH, non-invasive liver testing, Novo Nordisk, Obesity, Phase3, Semaglutide, toxic foods, Canagliflozin, Janssen Pharma, metabolic syndromes, multi-disciplinary care, primary care, healthcare insurers, ILC2021, hypercholesterolemia, dyslipidemia, hypertension

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast